The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug, Oxbryta from worldwide markets. Merck’s MRK Keytruda ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.

Summit Therapeutics (SMMT) stock traded lower as Citi downgraded the company to neutral from buy on valuation after recent surge of its shares. Read more here.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the ...